4//SEC Filing
OBrien Christopher Flint 4
Accession 0001209191-18-008219
CIK 0000914475other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 6:08 PM ET
Size
12.2 KB
Accession
0001209191-18-008219
Insider Transaction Report
Form 4
OBrien Christopher Flint
Sr. VP & Chief Medical Officer
Transactions
- Sale
Common Stock
2018-02-05$83.40/sh−1,113$92,819→ 54,310 total - Tax Payment
Common Stock
2018-02-06$82.48/sh−1,014$83,635→ 55,946 total - Sale
Common Stock
2018-02-05$83.01/sh−1,500$124,522→ 52,223 total - Award
Stock Option
2018-02-05+9,250→ 9,250 totalExercise: $81.49Exp: 2028-02-05→ Common Stock (9,250 underlying)
Footnotes (5)
- [F1]Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Sale of 1,113 shares of common stock issued upon vesting of restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (2,087) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F4]Payment of tax liability by withholding 1,014 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,636) maintained by the Reporting Person.
- [F5]Represents option of which 1/24th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/24th of the shares underlying the option becomes vested and exercisable each month thereafter.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001343124
Filing Metadata
- Form type
- 4
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 6:08 PM ET
- Size
- 12.2 KB